A Phase 1 Study of Apraglutide (Single Dose Study)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031220579

Enrollment

Registered

2023-01-22

Start date

2023-03-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

short bowel syndrome and intestinal failure (SBS-IF)

Interventions

Apraglutide (TA799) 2.5mg, 5mg, 10mg subcutaneously single administration and blood collection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects will be individuals who meet all of the following criteria. [1] Healthy Japanese men and women [2] Individuals >=18 to <45 years of age at the time of informed consent [3] Individuals who fully understand the details of the study and who are capable of providing written informed consent

Exclusion criteria

Exclusion criteria: Individuals meeting any of the following criteria will be excluded from the study. [1] Past history of disease in organsystems considered unsuitable for this study [2] Past history of disease or surgery that could affect pharmacokinetic or pharmacodynamic evaluation [3] Other protocol defined exclusion criteria could apply

Design outcomes

Primary

Measure	Time frame
Plasma concentration of compound(s)	—

Contacts

Public ContactClinical Trial Information Contact for

ASAHI KASEI THERAPEUTICS CORPORATION

ct-info@om.asahi-kasei.co.jp+81-3-6699-3600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026